SCHEMBL17809090

SCHEMBL17809090

Cc1cn([C@@H]2OC(COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)nc1N

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 2/20 0.57
ATIC P31939 1/20 0.57
P2RY2 P41231 5/20 0.56
P2RY6 Q15077 2/20 0.56
DNPH1 O43598 2/20 0.55
PRKAB2 O43741 1/20 0.55
TRPM2 O94759 1/20 0.55
LDHA P00338 1/20 0.55
ADRB2 P07550 1/20 0.55
SRC P12931 1/20 0.55
ADORA1 P30542 1/20 0.55
P2RY1 P47900 1/20 0.55
PRKAG1 P54619 1/20 0.55
PRKAA2 P54646 1/20 0.55
PDE4D Q08499 1/20 0.55
KCNH2 Q12809 1/20 0.55
PRKAA1 Q13131 1/20 0.55
PDE3A Q14432 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
TAS1R3 Q7RTX0 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14946157 1.00 FBP1 (0.57) FBP1ATICP2RY2P2RY6DNPH1
SCHEMBL903054 1.00 FBP1 (0.57) FBP1ATICP2RY2P2RY6DNPH1
SCHEMBL3504106 1.00 FBP1 (0.57) FBP1ATICP2RY2P2RY6DNPH1
SCHEMBL16489878 1.00 FBP1 (0.57) FBP1ATICP2RY2P2RY6DNPH1
SCHEMBL17789100 1.00 FBP1 (0.57) FBP1ATICP2RY2P2RY6DNPH1
SCHEMBL3504116 1.00 FBP1 (0.57) FBP1ATICP2RY2P2RY6DNPH1
SCHEMBL14661258 0.92 P2RY2 (0.65) P2RY2P2RY6P2RY1P2RY11P2RY4
SCHEMBL14661260 0.92 P2RY2 (0.65) P2RY2P2RY6P2RY1P2RY11P2RY4
SCHEMBL16805400 0.90 P2RY2 (0.50) FBP1ATICP2RY2P2RY6CA5A
SCHEMBL17210993 0.90 P2RY2 (0.50) FBP1ATICP2RY2P2RY6CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170252461-A1 HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA MODERNATX, INC. 2017-09-07 US disclosed
US-9572897-B2 Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins MODERNATX, INC. (US) 2017-02-21 US disclosed
US-20160158385-A1 MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS ARES CAPITAL CORPORATION, AS AGENT 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158385-A1 MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS POLRMT, POLN, PHAX FBP1 2938/4885ATIC 1192/4885P2RY2 3852/4885
US-20170252461-A1 HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA RNGTT, NSUN3, CPSF6 FBP1 388/4885ATIC 410/4885P2RY2 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.